About Us
MedMap is a Singapore-based biomedical innovation partner focused on two core business areas: Clinical Validation & Market Access and AI-driven Drug Optimization. We help medical technology and biopharmaceutical teams de-risk development, generate actionable evidence and accelerate market entry across Southeast Asia.
We partner with clinicians, researchers, AI scientists and industry leaders to translate biomedical innovation into real-world impact.
Our focused value proposition
MedMap combines regional healthcare execution with AI-enabled biomedical R&D capabilities. We focus resources on services where clinical evidence, regulatory strategy, data-driven insight and scientific optimization directly improve commercialization and development outcomes.
Clinical Validation & Market Access
We support medical device, IVD and healthtech companies with clinical validation planning, KOL engagement, regional readiness assessment, registration strategy and commercialization support across Southeast Asia.
AI-driven Drug Optimization
We provide AI-assisted small-molecule optimization services, integrating molecule generation, QSAR, ADMET prediction, docking, PK/PD simulation and closed-loop DMTA learning to help teams prioritize stronger drug candidates.
From evidence generation to AI-guided optimization, MedMap helps biomedical innovators make faster, better-informed decisions.
Our team bridges pharmaceutical R&D, clinical implementation, regulatory expectations and commercial realities so that promising technologies can move from concept to adoption with greater confidence.
Regional execution
Southeast Asia market access, clinical validation and stakeholder engagement.
Scientific depth
AIDD workflows, computational chemistry and multidisciplinary solution design.
Practical outcomes
Clear proposals, project roadmaps, evidence plans and optimization reports.